arrow
C

Charles Parker

university college london
H指数:13
被引数:2,488

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol

基于数字病理学的多模态人工智能衍生预后模型在开始长期雄激素剥夺治疗的晚期前列腺癌患者中的外部验证:STAMPEDE平台方案的四项Ⅲ期随机对照试验的回顾性附加生物标志物研究

2025-06-010
OAAI
Liver involvement in a large cohort of patients with erythropoietic protoporphyria or X-linked protoporphyria
2025-03-010
OAAI
Digital Pathology–based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer

基于数字病理的 Artificial Intelligence 生物标志物验证在转移性前列腺癌中的应用

2024-12-010
PRE
The Lancet Commission on prostate cancer: planning for the surge in cases

柳叶刀前列腺癌委员会: 规划病例激增

LANCET
IF88.5
2024-04-0157
OAAI
External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived model in high-risk localized (M0)/metastatic (M1) prostate cancer (PCa) starting androgen deprivation therapy (ADT) in the docetaxel (Doc) or abiraterone (AAP) phase III STAMPEDE trials

在多西他赛 (Doc) 或阿比曲酮 (AAP) III期踩踏试验中开始雄激素剥夺治疗 (ADT) 的高危局部 (M0)/转移性 (M1) 前列腺癌 (PCa) 中基于数字病理学的多模式人工智能 (MMAI) 衍生模型的外部验证

2023-10-012
OA
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
2020-06-11389
OAAI
Overall Health, Daily Functioning, and Quality of Life in Acute Hepatic Porphyria Patients: ENVISION, a Phase 3 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
2020-02-010
PREAI
EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks
2019-11-07112
OAAI
Disease Characteristics of Acute Hepatic Porphyria Patients: ENVISION, a Phase 3 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
2019-10-011
PREAI
Management of acute hepatic porphyria attacks in europe and united states: EXPLORE international, prospective, natural history study
2019-04-010
PREAI
ENVISION, a phase 3 study to evaluate efficacy and safety of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1, in acute hepatic porphyria patients
2019-04-016
PREAI
Acute hepatic porphyria disease manifestations and daily life impacts in EXPLORE international, prospective, natural history study
2019-04-010
PREAI
AN ANALYSIS OF HEALTHCARE UTILIZATION AND COSTS ASSOCIATED WITH PATIENTS WITH ACUTE HEPATIC PORPHYRIAS (AHPS) WITH RECURRENT ATTACKS IN EXPLORE: A PROSPECTIVE, MULTINATIONAL NATURAL HISTORY STUDY OF PATIENTS WITH AHP
2018-05-013
OAAI
Afamelanotide for Erythropoietic Protoporphyria
2015-07-02195
OAAI